Absorption, Metabolism, and Excretion of Darunavir, a New Protease Inhibitor, Administered Alone and with Low-Dose Ritonavir in Healthy Subjects

Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials

Bonaventura Clotet, Nicholas Bellos, Jean‐Michel Molina et al. · The Lancet · 2007 · 480 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +11

TMC114, a Novel Human Immunodeficiency Virus Type 1 Protease Inhibitor Active against Protease Inhibitor-Resistant Viruses, Including a Broad Range of Clinical Isolates

Sandra De Meyer, Hilde Azijn, Dominique Surleraux et al. · Antimicrobial Agents and Chemotherapy · 2005 · 357 citations

Life Sciences, Infectious Diseases, Molecular Biology +17

Structural and Thermodynamic Basis for the Binding of TMC114, a Next-Generation Human Immunodeficiency Virus Type 1 Protease Inhibitor

Nancy M. P. King, M. Prabu-Jeyabalan, E.A. Nalivaika et al. · Journal of Virology · 2004 · 228 citations · Full text

Life Sciences, Biochemistry, Medicinal Chemistry +16

Potent Inhibition of HIV-1 Replication by Novel Non-peptidyl Small Molecule Inhibitors of Protease Dimerization

Yasuhiro Koh, Shintaro Matsumi, Debananda Das et al. · Journal of Biological Chemistry · 2007 · 149 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Metabolism of Amprenavir in Liver Microsomes: Role of CYP3A4 Inhibition for Drug Interactions

Caroline J. Decker, Leena M. Laitinen, Gary Bridson et al. · Journal of Pharmaceutical Sciences · 1998 · 113 citations

Medicine, Pharmacokinetics, Pharmacology +16